Journal of Molecular Science

Journal of Molecular Science
Volume 33 Issue 3, Year of Publication 2023, Page 28-31
DoI-17.4687/1000-9035.2023.011

Journal of Molecular Science
www.jmolecularsci.com ISSN:1000-9035

Non-Coding RNA-Mediated Epigenetic Modulation of Chromatin Dynamics and Transcriptional Regulation in Development and Pathogenesis

Jacob William Baker, Emma Louise Foster, Benjamin Leo Carter, Grace Lily Morris

Article Information
Received: 17-07-2023
Revised: 05-08-2023
Accepted: 20-08-2023
Published: 23-09-2023

Keywords
Non-coding RNAs

ABSTRACT
Non-coding RNAs (ncRNAs) have emerged as key regulators of gene expression and chromatin organization. They orchestrate transcriptional and post-transcriptional mechanisms that modulate cellular differentiation, development, and disease progression. Long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and other ncRNAs contribute to epigenetic regulation by interacting with chromatin-modifying complexes, influencing DNA methylation, histone modifications, and higher-order chromatin architecture. Dysregulation of these processes has been implicated in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. This article reviews the role of ncRNAs in chromatin remodeling, their impact on gene regulation, and their implications in health and disease.

INTRODUCTION:

The central dogma of molecular biology has evolved beyond the classical view of gene regulation. While protein-coding genes constitute only a small fraction of the genome, the majority of transcribed RNAs are non-coding, playing essential roles in chromatin architecture and transcriptional regulation. NcRNAs, including lncRNAs, miRNAs, small interfering RNAs (siRNAs), and circular RNAs (circRNAs), interact with chromatin-modifying enzymes and transcription factors, thereby influencing gene expression. Understanding the mechanistic interplay between ncRNAs and chromatin structure is crucial for deciphering cellular functions and disease pathogenesis.

2. Classes and Functions of Non-Coding RNAs

2.1 Long Non-Coding RNAs (lncRNAs)



Fig.Long Non-Coding RNAs

Journal of Molecular Science
Journal of Molecular Science
Volume 33 Issue 3, Year of Publication 2023, Page 28-31
DoI-17.4687/1000-9035.2023.011

LncRNAs (>200 nucleotides) function as molecular scaffolds, guides, decoys, and enhancers. They modulate chromatin accessibility by interacting with polycomb repressive complexes (PRC1, PRC2), SWI/SNF chromatin remodelers, and transcriptional co-activators. Notable examples include XIST, which silences the X chromosome in female cells, and HOTAIR, which promotes metastasis in cancer.

2.2 MicroRNAs (miRNAs)



Fig.MicroRNAs (miRNAs)

MiRNAs (~22 nucleotides) regulate gene expression by binding to complementary sequences in messenger RNAs (mRNAs), leading to translational repression or degradation. They influence chromatin dynamics by targeting histone-modifying enzymes and DNA methyltransferases, thus playing roles in development and disease.

2.3 Circular RNAs (circRNAs) and Other Small RNAs



Fig.Circular RNAs (circRNAs)

CircRNAs, derived from back-splicing events, act as miRNA sponges, transcriptional regulators, and protein scaffolds. Small nuclear RNAs (snRNAs) and small nucleolar RNAs (snoRNAs) are also involved in chromatin interactions and gene silencing.

3. ncRNA-Mediated Regulation of Chromatin Architecture

3.1 Histone Modifications and Chromatin Accessibility

LncRNAs and miRNAs regulate histone modifications by recruiting or inhibiting histone acetyltransferases (HATs), histone deacetylases (HDACs), and histone methyltransferases (HMTs). For instance, HOTAIR recruits PRC2 to promote H3K27 methylation, leading to gene repression.

3.2 DNA Methylation and Epigenetic Memory

NcRNAs modulate DNA methylation by guiding DNA methyltransferases (DNMTs) to specific genomic loci. For example, lncRNA ANRIL interacts with PRC1 and DNMTs to silence tumor suppressor genes.

3.3 Higher-Order Chromatin Organization

Chromatin topology is influenced by ncRNAs that regulate CTCF-cohesin interactions and chromatin looping. LncRNA Firre, for instance, mediates nuclear organization by tethering genomic loci to specific nuclear compartments.

4. Non-Coding RNAs in Development and Disease

Non-coding RNAs (ncRNAs) play pivotal roles in gene regulation, chromatin remodeling, and cellular differentiation, influencing both normal development and pathological conditions. Their functions extend beyond transcriptional and post-transcriptional regulation, making them crucial in embryogenesis, cancer epigenetics, and disease pathogenesis.

4.1 Developmental Regulation

NcRNAs are indispensable for embryonic development, lineage specification, and organogenesis, functioning as regulatory molecules that coordinate gene expression programs.

LincRNA-p21 and p53-Dependent Transcription

Long intergenic non-coding RNA (lincRNA)-p21 serves as a downstream regulator of p53, repressing transcriptional targets involved in cell cycle progression and apoptosis. This mechanism is crucial for proper tissue differentiation and cellular homeostasis.

LncRNA Braveheart in Cardiac Differentiation

LncRNA Braveheart (Bvht) plays a fundamental role in cardiovascular lineage commitment, regulating key transcription factors required for heart development. Loss of Bvht results in defective cardiomyocyte differentiation, highlighting its role in early heart formation.

MiRNAs in Developmental Processes:

MicroRNAs (miRNAs) fine-tune gene expression during embryogenesis, ensuring precise control over cell fate decisions. For instance, miR-125b regulates hematopoiesis, while miR-430 facilitates maternal-to-zygotic transition in early embryonic stages.

Journal of Molecular Science
Volume 33 Issue 3, Year of Publication 2023, Page 28-31
DoI-17.4687/1000-9035.2023.011

4.2 Cancer Epigenetics

Aberrant ncRNA expression is implicated in cancer progression, metastasis, and resistance to therapy.

Oncogenic LncRNAs Disrupting Tumor Suppressor Networks

- MALAT1 (Metastasis-Associated Lung Adenocarcinoma Transcript 1) promotes cancer cell proliferation and metastasis by modulating alternative splicing and chromatin accessibility.
- MEG3 (Maternally Expressed Gene 3), a tumor-suppressive lncRNA, interacts with p53 pathways to inhibit oncogenic signaling. Its downregulation is linked to various malignancies, including gliomas and hepatocellular carcinoma.
- MiRNAs Modulating Chromatin and Transcription
- miR-34, a direct p53 target, induces cell cycle arrest and apoptosis, functioning as a potent tumor suppressor. Its downregulation is observed in cancers such as lung, breast, and pancreatic cancer.
- miR-21, an oncogenic miRNA, suppresses tumor suppressors like PTEN and PDCD4, facilitating tumor growth and chemoresistance.
- Epigenetic Reprogramming via ncRNAs Dysregulated ncRNAs alter DNA methylation, histone modifications, and chromatin remodeling, contributing to cancer progression. LncRNAs such as HOTAIR act as scaffolds for histone-modifying complexes, leading to transcriptional silencing of tumor suppressor genes.

4.3 Neurological and Cardiovascular Diseases

NcRNAs are critical regulators of neurodevelopment and cardiovascular function, with their dysregulation contributing to neurodegenerative disorders and heart diseases.

NcRNAs in Neurodegeneration

- BACE1-AS (β-site APP Cleaving Enzyme 1 Antisense RNA) promotes amyloid-beta production by stabilizing BACE1 mRNA, a key enzyme in Alzheimer's disease (AD) pathology.
- NEAT1 (Nuclear-Enriched Abundant Transcript 1) is implicated in neuroinflammation and synaptic dysfunction, exacerbating conditions like Parkinson's disease and Huntington's disease.

NcRNAs in Cardiovascular Disorders

- MIAT (Myocardial Infarction Associated Transcript) contributes to cardiac remodeling and ischemic injury, influencing vascular integrity and endothelial function.
- ANRIL (Antisense Non-Coding RNA in the INK4 Locus) is associated with atherosclerosis and coronary artery disease, modulating inflammation and smooth muscle proliferation.

5. Therapeutic Potential of ncRNAs

NcRNA-based therapies, including miRNA mimics, antisense oligonucleotides (ASOs), and CRISPR-based interventions, are being explored for disease treatment. RNA-targeting drugs like MRX34 (miR-34 mimic) and lncRNA inhibitors offer promising avenues for therapeutic intervention.

6. CONCLUSION:

Non-coding RNAs (ncRNAs) play a crucial role in epigenetic regulation by modulating chromatin structure, DNA methylation, and histone modifications, thereby influencing gene expression. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) act as key regulators in cellular processes, including development, differentiation, and disease progression. Their dysregulation has been implicated in various pathological conditions such as cancer, neurodegenerative disorders, and cardiovascular diseases. Given their ability to fine-tune gene expression networks, ncRNAs present promising therapeutic targets for precision medicine. Future research should focus on designing targeted RNA-based interventions, including small RNA mimics, antisense oligonucleotides, and CRISPR-based epigenome editing, to modulate chromatin states and restore cellular homeostasis. Advancements in RNA delivery systems and stability optimization will be essential for translating these approaches into effective clinical applications.

REFERENCES

1. Rinn, J. L., & Chang, H. Y. (2012). Genome Regulation by Long Noncoding RNAs. *Annual Review of Biochemistry*, 81, 145-166.
2. Esteller, M. (2011). Non-coding RNAs in human disease. *Nature Reviews Genetics*, 12(12), 861-874.
3. Kopp, F., & Mendell, J. T. (2018). Functional classification and experimental dissection of long noncoding RNAs. *Cell*, 172(3), 393-407.
4. Cech, T. R., & Steitz, J. A. (2014). The noncoding RNA revolution-trashing old rules to forge new ones. *Cell*, 157(1), 77-94.
5. Lander, E. S., et al. (2001). Initial sequencing and analysis of the human genome. *Nature*, 409(6822), 860-921.
6. Guttman, M., & Rinn, J. L. (2012). Modular regulatory principles of large non-coding RNAs. *Nature*, 482(7385), 339-346.
7. Bartel, D. P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. *Cell*, 116(2), 281-297.
8. Mercer, T. R., Dinger, M. E., & Mattick, J. S. (2009). Long non-coding RNAs: Insights into functions. *Nature Reviews Genetics*, 10(3), 155-159.
9. Schmitt, A. M., & Chang, H. Y. (2016). Long noncoding RNAs in cancer pathways. *Cancer Cell*, 29(4), 452-463.
10. Zhao, J., Sun, B. K., Erwin, J. A., et al. (2008). Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. *Science*, 322(5902), 750-756.
11. Derrien, T., Johnson, R., Bussotti, G., et al. (2012). The GENCODE v7 catalog of human long noncoding RNAs. *Genome Research*, 22(9), 1775-1789.
12. Brannan, C. I., Dees, E. C., Ingram, R. S., et al. (1990). The product of the H19 gene may function as an RNA. *Molecular and Cellular Biology*, 10(1), 28-36.

Journal of Molecular Science
Volume 33 Issue 3, Year of Publication 2023, Page 28-31
DoI-17.4687/1000-9035.2023.011

13. Rajagopal, N., et al. (2016). High-throughput mapping of regulatory DNA. *Cell*, 165(6), 1825-1839.